T1	intervention 0 9	Tamoxifen
T2	eligibility 359 400	women at increased risk for breast cancer
T3	No-of-participants 598 604	13,388
T4	control 640 647	placebo
T5	duration 665 672	5 years
T6	outcome 1001 1042	cumulative rate of invasive breast cancer
T9	outcome 1190 1234	cumulative rate of noninvasive breast cancer
T12	intervention-value 1461 1464	32%
T13	outcome 1465 1500	reduction in osteoporotic fractures
T14	adverse-effect 1555 1561	stroke
T15	adverse-effect 1563 1583	deep-vein thrombosis
T16	adverse-effect 1589 1598	cataracts
T17	adverse-effect 1639 1661	ischemic heart disease
T18	adverse-effect 1666 1671	death
T19	outcome 1759 1786	Risks of pulmonary embolism
T7	control-value 1060 1064	42.5
T20	control-participants 1069 1073	1000
T8	intervention-value 1104 1108	24.8
T21	intervention-participants 1113 1117	1000
T10	control-value 1252 1256	15.8
T22	control-participants 1261 1265	1000
T11	intervention-value 1296 1300	10.2
T23	intervention-participants 1305 1309	1000
